“Once patients have survived cancer, they don't die from cancer, they die from heart disease. Cardio-oncology is about making sure that doesn't happen," said Juan Carlos Plana, M.D.

Although cardiovascular disease is largely avoidable through lifestyle modifications, it remains the nation’s number one cause of death. While annual wellness exams offer physicians the chance to advise patients on modifying cardiac risk factors, that advice can easily get lost given the amount of information covered during a routine check-up.

 

C. R. Bard Inc. announced the U.S. Food and Drug Administration (FDA) approval of the Lutonix 035 drug-coated balloon (DCB) catheter for percutaneous transluminal angioplasty (PTA) after pre-dilatation, for the treatment of de novo or restenotic lesions up to 150 mm in length in native vascular disease of the superficial femoral or popliteal arteries with reference vessel diameters of 4 mm to 6mm.

October 10, 2014—Mitralign Inc. reported on the successful use of its technology to perform a percutaneous repair on a patient with tricuspid regurgitation (TR). Prof. Dr. med. J. Schofer of the Medicare Center and Department for Percutaneous Interventions of Structural Heart Disease, Albertinen Heart Center, Hamburg, Germany; and Rebecca Hahn, M.D., director of interventional echocardiography, Columbia University Medical Center / New York Medical Center / New York Presbyterian Hospital, presented at the PCR London Valves Conference and detailed the procedure—a percutaneous bicuspidization of the tricuspid valve, successfully converting a regurgitating tri-leaflet valve into a functioning bi-leaflet valve. The German regulatory body BfArM approved the patient for a compassionate use exemption, as no other options were available. The successful procedure was performed at the Albertinen Heart Center in Hamburg. The Mitralign product is currently being evaluated in clinical trials for an indication in functional mitral regurgitation. The device is not approved for sale or distribution.

October 10, 2014 — Despite ongoing commercial challenges in 2013, the global medtech industry’s financial performance held steady at the relatively low levels of growth that have become common in recent years. But even as the industry grapples with these market and regulatory pressures, it faces a potential growing challenge: the threat of commoditization, according to new findings outlined in EY’s annual medical technology report, Pulse of the industry: differentiating differently, released today.

A KLAS report revealed a lack of widespread integration with EMRs continues to limit the effectiveness of order sets and care plans.

Direct Flow Medical Inc., a transcatheter heart valve innovator focused on improving patient outcomes has received the CE Mark for an enhanced transfemoral delivery system for the Direct Flow Medical Transcatheter Aortic Valve System.

The swift migration to cloud computing and data recovery services shows no signs of slowing, with half of organizations reporting they expect to boost their cloud services budgets over the next 18 months, according to a new study conducted by IDG Research Services on behalf of Sungard Availability Services and EMC Corp.

LoneStar Heart Inc. announced that it received the CE mark (Conformite Europeene) for its Algisyl-LVR hydrogel implant, the company's lead product for the treatment of advanced heart failure (HF). 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now